Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939422 | 0.98 | CYP1A2 (0.41) | CYP1A2CYP2D6 | |
| Methyl Alcohol SCHEMBL28396245 | 0.96 | CYP1A2 (0.37) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6806460 | 0.77 | CYP1A2 (0.52) | CYP1A2CYP2D6 | |
| SCHEMBL287060 | 0.75 | — | — | |
| SCHEMBL3832949 | 0.75 | CYP1A2 (0.53) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL28210727 | 0.74 | TRPA1 (0.34) | — | |
| Hydrochloric Acid SCHEMBL8537869 | 0.74 | CYP1A2 (0.38) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4275672 | 0.72 | — | — | |
| SCHEMBL6443991 | 0.71 | CYP1A2 (0.39) | CYP1A2CYP2D6 | |
| SCHEMBL28210729 | 0.71 | TRPA1 (0.36) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 538 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112125881-A | 4-pyridine substituted phthalazinone compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2020-12-25 | — | — | CN | claimed |
| EP-1501548-B1 | CHEMICALLY ACTIVATED CARBOXYPOLYSACCHARIDES AND USES | FZIOMED INC (US) | 2014-06-04 | — | — | EP | claimed |
| EP-4387673-A1 | PROCESS FOR THE PREPARATION OF PEGYLATED ADRENOMEDULLIN, ITS INTERMEDIATES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2024-06-26 | — | — | EP | disclosed |
| EP-3506922-B1 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | ST JUDE CHILDRENS RES HOSPITAL (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-3615527-B1 | NEW AZAQUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-03-06 | — | — | EP | disclosed |
| EP-3442974-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230141809-A1 | QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-05-11 | — | — | US | disclosed |
| CN-112125881-B | 4-pyridine substituted phthalazinone compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-03-28 | — | — | CN | disclosed |
| EP-3790874-B1 | ANTHELMINTIC QUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-03-15 | — | — | EP | disclosed |
| WO-2023021173-A1 | PROCESS FOR THE PREPARATION OF PEGYLATED ADRENOMEDULLIN, ITS INTERMEDIATES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | WO | disclosed |
| US-11572357-B2 | Quinoline derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2023-02-07 | — | — | US | disclosed |
| EP-0358660-A4 | SYNTHETIC INHIBITORS OF MAMMALIAN COLLAGENASE | — | 1991-01-09 | — | — | EP | disclosed |
| US-4970215-A | Substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives and anti-allergic use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-13 | — | — | US | disclosed |
| US-4965258-A | Anticoagulant; thromboxane a2 antagonist | BAYER AKTIENGESELLSCHAFT (DE) | 1990-10-23 | — | — | US | disclosed |
| EP-0358660-A1 | SYNTHETIC INHIBITORS OF MAMMALIAN COLLAGENASE. | RES CORP TECHNOLOGIES INC (US) | 1990-03-21 | — | — | EP | disclosed |
| US-4904797-A | REACTING A (BENZENESULFONAMIDOALKYL)CYCLOALKANO(1,2-B)INDOLE WITH ACRYLONITRILE; HYDROLYSIS, HYDROGENATION, REDUCTION | BAYER AKTIENGESELLSCHAFT (DE) | 1990-02-27 | — | — | US | disclosed |
| US-4827032-A | INTERMEDIATES FOR ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-05-02 | — | — | US | disclosed |
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | disclosed |
| WO-1988006890-A1 | SYNTHETIC INHIBITORS OF MAMMALIAN COLLAGENASE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1988-09-22 | — | — | WO | disclosed |
| CN-85107547-A | Microchemiluminescent detection system | — | 1987-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141809-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, QTRT2 | CYP1A2 32/4885CYP2D6 71/4885 |
| US-11572357-B2 | Quinoline derivatives | RECQL, NQO2, QTRT2 | CYP1A2 35/4885CYP2D6 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.